Y-MABS THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.71 USD | -0.88% |
|
-2.78% | +115.69% |
Chart calendar Y-mAbs Therapeutics, Inc.
1844ea6fbedfb84f19.8a-cjG5zcpTV9Cea8n2hb6eVDNQh8YuxJiXFotJ9Hy4.w_jW6z0HGaWUuXfjhDLRPcDNQb5ipNLIaUKu-4s2e1-wltnjXTI__o-TVA~571ef5d8ee21b62ecff66615492133f6
Upcoming events on Y-mAbs Therapeutics, Inc.
Past events on Y-mAbs Therapeutics, Inc.
| 01/03/2024 13:00 | Q4 2023 Earnings Call |
| 29/02/2024 21:05 | Q4 2023 Earnings Release |
| 11/01/2024 01:15 | JPMorgan Healthcare Conference |
| 14/11/2023 14:00 | Q3 2023 Earnings Call |
| 13/11/2023 21:05 | Q3 2023 Earnings Release |
| 08/11/2023 05:00 | BMO BioPharma Spotlight Series: Oncology |
| 10/10/2023 | International Society of Pediatric Oncology Congress - Poster No: P149 / 1609 |
| 10/10/2023 | International Society of Pediatric Oncology Congress - Poster No: P148 / 1060 |
| 10/10/2023 | International Society of Pediatric Oncology Congress - Poster No: P1450/ 1641 |
| 11/09/2023 | Morgan Stanley Global Healthcare Conference |
| 11/09/2023 16:30 | H.C. Wainwright Global Investment Conference |
| 11/08/2023 14:00 | Q2 2023 Earnings Call |
| 10/08/2023 21:01 | Q2 2023 Earnings Release |
| 09/08/2023 14:30 | Canaccord Genuity’s Growth Conference |
| 07/08/2023 | Wedbush PacGrow Healthcare Conference |
| 08/06/2023 15:00 | Annual General Meeting |
| 01/06/2023 | American Society of Clinical Oncology Conference |
| 09/05/2023 14:00 | Q1 2023 Earnings Call |
| 08/05/2023 21:01 | Q1 2023 Earnings Release |
| 18/04/2023 18:30 | AACR Meeting |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,00 0,00 - | 20,8 10,9 90.21% | 34,9 62,2 -43.91% | 65,3 53,4 22.26% | 84,8 82,6 2.69% | 96,9 |
|
EBITDA Million USD | Released Forecast Spread | -82,8 -86,2 3.89% | -120 -138 13.26% | -115 -93,8 -22.22% | -94,0 -115 18.35% | -24,9 -29,8 16.33% | 288 |
|
EBIT Million USD | Released Forecast Spread | -83,0 -84,9 2.18% | -120 -127 5.89% | -115 -84,5 -36.62% | -94,8 -115 17.24% | -25,7 -31,3 18.09% | -23,8 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -81,0 -83,1 2.5% | -119 -120 0.81% | -55,3 -47,2 -17.11% | -95,6 -114 16.25% | -20,9 -29,0 28.11% | -23,8 |
|
Net income Million USD | Released Forecast Spread | -81,0 -83,2 2.64% | -119 -126 5.01% | -55,3 -48,8 -13.3% | -95,6 -115 17.17% | -21,4 -29,1 26.25% | -23,1 |
|
EPS USD | Released Forecast Spread | -2,30 -2,35 2.02% | -2,97 -3,16 6.05% | -1,28 -1,10 -16.34% | -2,19 -2,65 17.36% | -0,49 -0,66 25.48% | -0,52 |
| Announcement Date | 12/03/20 | 25/02/21 | 24/02/22 | 30/03/23 | 29/02/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 9,60 10,8 -11.29% | 10,5 10,9 -3.8% | 10,8 11,2 -3.73% | 12,5 12,0 4.4% | 31,4 20,3 54.54% | 20,3 15,6 30.2% | 20,8 20,3 1.98% | 20,5 20,9 -2.27% | 23,4 21,0 11.49% | 22,2 | 24,0 | 25,0 | 25,8 | 25,1 |
|
EBITDA Million USD | Released Forecast Spread | -35,5 -32,0 -10.83% | -27,5 -28,0 1.79% | -39,8 -30,0 -32.52% | -25,8 -32,0 19.4% | -0,92 -19,0 95.14% | -7,32 -15,0 51.21% | -7,00 -11,0 36.37% | |||||||
|
EBIT Million USD | Released Forecast Spread | -35,8 -30,4 -17.53% | -27,7 -30,7 9.69% | -39,9 -28,8 -38.91% | -26,0 -30,2 13.87% | -1,15 -20,0 94.24% | -7,50 -14,2 47.15% | -7,22 -11,0 34.45% | -7,75 -7,55 -2.6% | -3,20 -9,01 64.48% | -6,71 | -6,16 | -6,27 | -6,07 | |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -36,9 -28,9 -27.63% | -28,1 -30,6 8.17% | -41,1 -28,0 -46.96% | -27,5 -31,2 11.9% | 1,16 -18,3 106.34% | -6,39 -14,6 56.24% | -6,12 -10,8 43.26% | -7,56 -8,54 11.47% | -0,79 -8,94 91.13% | -6,09 | -5,95 | -6,06 | -5,71 | |
|
Net income Million USD | Released Forecast Spread | -36,9 -30,2 -22.26% | -28,1 -30,4 7.71% | -41,1 -28,5 -44.31% | -27,5 -29,9 7.84% | 1,16 -19,1 106.05% | -6,39 -13,7 53.39% | -6,30 -10,5 39.97% | -7,75 -7,49 -3.43% | -0,99 -8,80 88.77% | -6,09 | -5,95 | -6,06 | -5,71 | |
|
EPS USD | Released Forecast Spread | -0,85 -0,69 -23.88% | -0,64 -0,69 7.78% | -0,94 -0,65 -43.78% | -0,63 -0,70 9.64% | 0,03 -0,44 106.84% | -0,15 -0,32 52.91% | -0,14 -0,25 43.81% | -0,18 -0,17 -4.65% | -0,02 -0,21 90.24% | -0,15 | -0,15 | -0,15 | -0,14 | -0,11 |
| Announcement Date | 24/02/22 | 09/05/22 | 08/08/22 | 07/11/22 | 30/03/23 | 08/05/23 | 10/08/23 | 13/11/23 | 29/02/24 | - | - | - | - | - |
More events
Past sector events for Y-mAbs Therapeutics, Inc.
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- YMAB Stock
- Calendar Y-mAbs Therapeutics, Inc.
